A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC
Filippo De Marinis, Haiyan Tu, Konstantin K Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Inna Egorova, Eng-Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng-Ta Yang, BJ Srinivasa, Antonio Passaro, Laura Clementi, Wenbo Tang, Dennis Chin-Lun Huang, Agnieszka Cseh, Caicun Zhou, Yi-Long Wu
Learn more about the science behind this poster in the videos, papers and other materials below.
FOR HEALTHCARE PROFESSIONALS ONLY
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue